Correlation between ZAP-70, phospho-ZAP-70, and phospho-syk expression in leukemic cells from patients with CLL

Cytometry Part B - Clinical Cytometry

Volumn 78, Issue 2, 2010, Pages 115-122

  Kaplan, David ^a   Meyerson, Howard J ^a   Li, Xiaofeng ^a   Drasny, Carly ^a   Liu, Fangfang ^a   Costaldi, Mark ^a   Barr, Paul ^a   Lazarus, Hillard M ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antigen receptor signaling pathway; Chronic lymphocytic leukemia; Enzymatic amplification staining; P21cip1; Phospho antigens; Syk; ZAP 70

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; LYMPHOCYTE ANTIGEN RECEPTOR; PROTEIN KINASE SYK; PROTEIN KINASE ZAP 70; PROTEIN P53;

ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; IN VITRO STUDY; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

FLOW CYTOMETRY; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKOCYTES, MONONUCLEAR; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; SENSITIVITY AND SPECIFICITY; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 77749280252     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.20506     Document Type: Article

References (32)

1. Chiorazzi N, Ferrarini M. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol 2003;21:841-894.
2. Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 2004;103:4389-4395.
3. Rasenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, Neuberg DS, Flinn IW, Rai KR, Byrd JC, Kay NE, Greaves A, Weiss A, Kipps TJ. ZAP-70 compared with immunoglobulin heavychain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004;351:893-901.
4. Chan AC, Iwashima M, Turck CW, Weiss A. ZAP-70: a 70 kd protein tyrosine kinase that associates with the TCR zeta chain. Cell 1992;71:649-662.
5. Chan AC, van Oers NS, Tran A, Turka L, Law CL, Ryan JC, Clark EA, Weiss A. 1994. Differential expression of ZAP-70 and Syk protein tyrosine kinases, and the role of this family of protein tyrosine kinases in TCR signaling. J Immunol 1994;152:4758-4766.
6. Chen L, Widhopf G, Huynh L, Rassenti L, Rai KR, Weiss A, Kipps TJ. Expression of ZAP-70 is associated with increased B-cell signaling in chronic lymphocytic leukemia. Blood 2002;100:4609-4614.
7. Chen L, Huynh L, Apgar J, Tang L, Rassenti L, Weiss A, Kipps TJ. ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood 2008;111:2685-2692.
8. Lanham S, Hamblin T, Oscier D, Ibbotson R, Stevenson F, Packham G. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood 2003;101:1087-1093.
9. Gobessa S, Laurenti L, Longo PG, Sica S, Leone G, Efremov DG. ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. Blood 2007;109:2032-2039.
10. Meyerson HJ, MacLennan G, Husel W, Tse W, Lazarus HM, Kaplan D. D cyclins in CD5+ B-cell lymphocproliferative disorders. Cyclin D1 and cyclin D2 identfy diagnostic gropus and cyclin D1 correlates with ZAP-70 expression in chronic lymphocytic leukemia. Am J Clin Pathol 2006;125:241-250.
11. Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H, Theil J, Vardiman, J. 2008. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon France: IARC Press; 2008. pp 441.
12. Kaplan D. 2003. Enzymatic amplification staining for cell surface antigens. In: Robinson JP, editor. Current Protocols in Cytometry. New York, NY: Wiley; 2003. pp6.14.1-6.14.11.
13. Kaplan D, Meyerson H, Husel W, Lewandowska K, MacLennan G. D cyclins in lymphocytes. Cytometry A 2005;63A:1-9.
14. Kaplan D, Smith D, Meyerson H, Pecora N, Lewandowska, K. CD5 expression by B lymphocytes and its regulation upon Epstein-Barr virus transformation. Proc Natl Acad Sci USA 2001;98:13850-13853.
15. Best OG, Ibbotson RE, Parker AE, Davis ZA, Orchard JA, Oscier DG. ZAP-70 by flow cytometry: a comparison of different antibodies, anticoagulants, and methods of analysis. Cytometry B 2006;70B:235-241.
16. Shankey TV, Forman M, Scibelli P, Cobb J, Smith CM, Mills R, Holdaway K, Bernal-Hoyos E, Van Der Heiden M, Popma J, Keeney M. An optimized whole blodd method for flow cytometric measurement of ZAP-70 protein expression in chronic lymphocytic leukemia. Cytometry B 2006;70B:259-269.
17. Bakke AC, Purtzer Z, Leis J, Huang J. A robust ratio metric method for analysis of Zap-70 expresion in chronic lymphocytic leukemia (CLL). Cytometry B 2005;70B:227-234.
18. Kay S, Herishanu Y, Pick M, Rogowshi O, Baron S, Naparstek E, Polliack A, Deutsch VR. Quantitative flow cytometry of ZAP-70 levels in chronic lymphocytic leukemia using molecules of equivalent soluble fluorochrome. Cytometry B 2006;70B:218-226.
19. Preobrazhensky SN, Bahler DW Optimization of .ow cytometric measurement of ZAP-70 in chronic lymphocytic leukemia. Cytometry B 2008;74B:118-127.
20. Scielzo D, Camporeale A, Geuna M, Alessio M, Poggi A, Zocchi MR, Chilosi M, Caligaris-Cappio F, Ghia P. ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage. Leukemia 2006;20:689-695.
21. H mutations. Cytometry B 2006;70B:284-292.
22. Pettitt AR, Sherrington PD, Stewart G, Cawley JC, Taylor MR, Stankovic T. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood 2001;98:814-822.
23. Cip1/WAF1/Sdi1. J Pathol 1997;183:134-140.
24. Rao N, Dodge I, Band H. The Cbl family of ubiquitin ligases: critical negative regulators of tyrosine kinase signaling in the immune system. J Leukoc Biol 2002;71:753-763.
25. Coopman PJP, Do MTH, Barth M, Bowden ET, Hayes AJ, Basyuk E, Blancato JK, Vezza PR, McLeskey SW, Mangeat PH, Mueller SC. The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells. Nature 2000;406:742-747.
26. Bailet O, Fenouille N, Abbe P, Robert G, Rocchi S, Gonthier N, Denoyelle C, Ticchioni M, Ortonne J, Ballotti R, Deckert M, Tartare-Deckert S. Spleen tyrosine kinase functions as a fumor suppressor in melanoma cells by inducing senescence-like growth arrest. Cancer Research 2009;69:2748-2756.
27. Besson A, Dowdy SF, Roberts JM. CDK inhibitors: cell cycle regulators and beyond. Dev Cell 2008;14:159-169.
28. Yanagi S, Inatome R, Takano T, Yamamura H. Syk expression and novel function in a wide variety of tissues. Biochem Biophys Res Commun 2001;288:495-498.
29. Tohyama Y, Yamamura H. Protein tyrosine kinase, Syk: a key player in phagocytic cells. J Biochem 2009;145:267-273.
30. Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda WG, Gandhi V, Burger JA. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 2009;114:1029-1037.
31. Buchner M, Fuchs S, Prinz G, Pfeifer D, Bartholome K, Burger M, Chevalier N, Vallat L, Timmer J, Gribben JG, Jumaa H, Veelken H, Dierks C, Zirlik K. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res 2009;69:5424-5432.
32. Gibbs G, Bromidge T, Howe D, Hopkins J, Johnson S. Comparison of flow cytometric methods for the measurement of ZAP-70 expression in a routine diagnostic laboratory. Clin Lab Haematol 2005;27:258-266.